IntegraGen: 2024 Half-Year Results - Sales up 6% on a Like-for-Like Basis (Excluding SeqOIA) and Profitability Maintained

IntegraGen, a leading player in the genomic research and molecular diagnostics sector, has reported robust sales growth and maintained profitability for the first half of 2024. The company's focus on genomic research services and diagnostic solutions, coupled with strategic cost-cutting measures, has driven its success.

IntegraGen's sales growth can be attributed to its genomic research services and diagnostic solutions. The company's high-speed genotyping services, medium-speed genotyping services, and ultra-high-speed sequencing services have been in high demand from academic research institutions and pharmaceutical groups. Additionally, the sales of diagnostic solutions have contributed significantly to the overall sales growth.

The France market has played a pivotal role in IntegraGen's overall sales growth, accounting for 84.7% of net sales. The company's strong presence in the French market, coupled with its innovative products and services, has enabled it to maintain a significant market share.

IntegraGen's focus on oncology has also impacted its sales performance positively. The company's expertise in identifying genetic biomarkers and developing molecular diagnostic products and services in the field of oncology has attracted numerous clients, contributing to its sales growth.


IntegraGen has maintained its profitability despite the sales growth through strategic cost-cutting measures and operational efficiencies. The company has implemented measures to enhance quality, reliability, and resilience in its manufacturing operations and supply chain. Additionally, IntegraGen has focused on advancing its new product pipeline and integrating the Acclarent business, which has contributed to its profitability.


In conclusion, IntegraGen's 2024 half-year results demonstrate the company's strong performance in the genomic research and molecular diagnostics sector. The company's focus on genomic research services, diagnostic solutions, and strategic cost-cutting measures have contributed to its sales growth and maintained profitability. The France market and the company's expertise in oncology have further bolstered its performance. As IntegraGen continues to innovate and expand its offerings, it is well-positioned to maintain its competitive edge in the market.